Administration and concomitant administration

THE CDC'S ACIP RECOMMENDS PREVNAR 13® (PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE [DIPHTHERIA CRM197 PROTEIN]) FOR IMMUNOCOMPROMISED ADULTS AGED ≥19 AND FOR IMMUNOCOMPETENT ADULTS AGED ≥65 BASED ON SHARED CLINICAL DECISION-MAKING1

Prevnar 13® is a vaccine approved for adults 18 years of age and older for the prevention of pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine. Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication.

Administration considerations for
​​​​​​​Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])2

  • Approved as a single dose   
  • Packaged as a pre-filled syringe
  • The tip cap and rubber plunger of the pre-filled syringe are not made with natural rubber latex
  • Shake vigorously prior to use to obtain a homogenous, white suspension in the vaccine container
  • Do not use the vaccine if it cannot be suspended or if particulate matter or discoloration is found
  • For intramuscular use only
  • The preferred site for injection in adults is the deltoid muscle of the upper arm. Do not inject in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel
  • ​​​​​​After being shipped, Prevnar 13® may arrive at temperatures between 2ºC and 25ºC (36ºF and 77ºF)
  • Store refrigerated at 2ºC to 8ºC (36ºF to 46ºF)
  • Prevnar 13® should not be allowed to freeze. If vaccine has frozen, it must be discarded
  • ​​​Prevnar 13® is stable at temperatures up to 25ºC (77ºF) for 4 days. These data are not recommendations for shipping or storage, but may guide decisions for use in case of temporary temperature excursions2

Vaccinating against influenza may create an opportunity to also vaccinate appropriate adults with Prevnar 13®

According to the CDC,

“The target groups for pneumococcal vaccines ([Pneumovax® 23 (Pneumococcal Vaccine Polyvalent) or Prevnar 13®]) and influenza vaccine overlap. Both pneumococcal vaccines can be given at the same time as influenza vaccine but at different sites if indicated. [Pneumovax 23] should never be given during the same visit as [Prevnar 13®]."3

  • In clinical studies, coadministration of Prevnar 13® with influenza vaccine (IIV3 and IIV4) demonstrated noninferior immune response for2:
    • All Prevnar 13® serotypes in adults aged 50 and older (IIV4), and adults aged 50-59 (IIV3)
    • 12 of 13 Prevnar 13® serotypes in adults aged 65 and older (IIV3)
      ​​​​​​​
  • Prevnar 13® is a 1-time dose for adults; it is not an annual vaccine2
  • ​​​​​​​When Prevnar 13® is administered at the same time as another injectable vaccine(s), the vaccines should always be administered with different syringes and at different injection sites2

Vaccinating against herpes zoster may also create an opportunity to vaccinate appropriate patients with Prevnar 13®

  • There are 2 different herpes zoster vaccines4
  • ​​​​​​​The safety and efficacy of concomitant administration of Prevnar 13® and herpes zoster vaccines are not included in the full Prescribing Information for Prevnar 13® and have not been studied

According to the CDC,

“[SHINGRIX® (Zoster Vaccine Recombinant, Adjuvanted)] and pneumococcal vaccine may be administered at the same visit if the person is eligible for both. When both pneumococcal conjugate vaccine PCV13 and PPSV23 are recommended for an adult, PCV13 should always be administered first and may be administered concomitantly with [SHINGRIX]." 5

Patient profiles

Learn more about adult patients who may be appropriate candidates for vaccination with Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])

View patient profiles

Pneumovax® is a registered trademark of Merck & Co., Inc. SHINGRIX is a registered trademark of GSK group of companies.
​​​​​​​
ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention. IIV3=inactivated influenza vaccine, trivalent; IIV4=inactivated influenza vaccine, quadrivalent; PCV13=13-valent pneumococcal conjugate vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine.

Order Prevnar 13®

Order vaccines directly through Pfizer's online ordering system

Order now

References:

  1. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:1069-1075. doi: http://dx.doi.org/10.15585/mmwr.mm6846a5.
  2. Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Prescribing Information, Wyeth Pharmaceuticals LLC, 2019.
  3. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington, DC: Public Health Foundation, 2015.
  4. Food and Drug Administration (FDA). Vaccines licensed for use in the United States. FDA website. https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm093833.htm. Accessed January 7, 2020.
  5. Centers for Disease Control and Prevention. Administering Shingrix. Centers for Disease Control and Prevention Vaccines and Preventable Diseases website. https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/administering-vaccine.html. Accessed January 7, 2020.

Indication

  • In adults 18 years of age and older, Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine
  • Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
  • In adults, the most commonly reported solicited adverse reactions were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash

Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967. This website is neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of this site.

Please see full Prescribing Information for Prevnar 13®.

  • In adults 18 years of age and older, Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine